Iterum Therapeutics plc (NASDAQ:ITRM) Sees Significant Decline in Short Interest

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 1,580,000 shares, a drop of 14.6% from the February 13th total of 1,850,000 shares. Approximately 4.7% of the company’s shares are short sold. Based on an average trading volume of 783,000 shares, the days-to-cover ratio is currently 2.0 days.

Iterum Therapeutics Stock Performance

Shares of ITRM stock opened at $1.45 on Thursday. Iterum Therapeutics has a 52-week low of $0.81 and a 52-week high of $3.02. The stock has a market cap of $50.14 million, a PE ratio of -1.11 and a beta of 2.44. The firm’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $1.48.

Institutional Investors Weigh In On Iterum Therapeutics

Several hedge funds have recently bought and sold shares of the company. Lee Financial Co acquired a new stake in Iterum Therapeutics in the fourth quarter worth $28,000. Sanctuary Advisors LLC acquired a new stake in Iterum Therapeutics in the fourth quarter worth $35,000. Citadel Advisors LLC acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $38,000. Two Sigma Investments LP acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $45,000. Finally, Apollon Financial LLC raised its holdings in shares of Iterum Therapeutics by 11.3% during the fourth quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock worth $443,000 after acquiring an additional 25,500 shares during the period. 9.21% of the stock is currently owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.